Analysts See $-0.57 EPS for Sarepta Therapeutics, Inc. (SRPT) on July, 18

June 27, 2018 - By Don Salinas

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Corporate Logo
Big Money Sentiment decreased to 0.97 in Q1 2018. It has change of 0.25, from 2017Q4’s 1.22. The ratio dived due to Sarepta Therapeutics, Inc. positioning: 31 sold and 81 reduced. 45 funds amassed positions and 64 increased positions. Investors holded 52.88 million in 2017Q4 but now own 54.74 million shares or 3.52% more.
Great West Life Assurance Can holds 6,948 shs. Prudential Fincl reported 53,215 shs stake. Jabre Prtn Sa holds 0.09% or 5,900 shs. Atika Cap Mngmt Ltd reported 2.46% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Massmutual Co Fsb Adv has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Los Angeles Cap Equity Rech stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Moreover, Citigroup has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 96,213 shs. Cambridge Invest Rech stated it has 10,551 shs. Elk Creek Prtnrs Ltd holds 1.41% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 325,356 shs. Stevens Capital Mgmt Limited Partnership holds 0.02% or 5,455 shs in its capital. Amundi Pioneer Asset Mgmt Incorporated holds 0.01% or 49,662 shs. Moreover, Mutual Of America Management Limited Com has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Lucas stated it has 0.36% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Stratos Wealth Ptnrs Ltd holds 0% or 500 shs. North Star Inv Management Corporation accumulated 935 shs.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s earnings report is awaited on July, 18., as reported by Faxor. Last year’s earnings per share was $-1.15, while now analysts expect change of 50.43 % up from current $-0.57 earnings per share. After $-0.44 earnings per share was announced previous quarter, analysts now see negative EPS growth of 29.55 % for Sarepta Therapeutics, Inc.. The stock decreased 3.69% or $5 during the last trading session, hitting $130.53.Sarepta Therapeutics, Inc. has volume of 768,120 shares. Since June 27, 2017 SRPT has risen 197.08% and is uptrending. SRPT outperformed by 184.51% the S&P 500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Total analysts of 20 have positions in Sarepta Therapeutics (NASDAQ:SRPT) as follows: 18 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 90%. Since January 3, 2018 according to StockzIntelligence Inc Sarepta Therapeutics has 36 analyst reports. On Friday, May 4 Morgan Stanley maintained the shares of SRPT in report with “Equal-Weight” rating. On Tuesday, March 13 the rating was maintained by Leerink Swann with “Outperform”. On Wednesday, June 20 the stock has “Buy” rating by WBB Securities. On Wednesday, June 20 Cowen & Co maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating. Cowen & Co has “Buy” rating and $17800 target. On Tuesday, March 6 the rating was maintained by Morgan Stanley with “Overweight”. On Wednesday, March 7 the stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by SunTrust. On Wednesday, February 21 the stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given by J.P. Morgan. On Wednesday, February 21 the stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Overweight” rating by JP Morgan. The stock rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 13. In Friday, January 19 report Leerink Swann maintained the stock with “Buy” rating.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases.The company has $8.55 billion market cap. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.Currently it has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

For more Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news released recently go to: Fool.com, Seekingalpha.com, Fool.com, Fool.com or Seekingalpha.com. The titles are as follows: “Is Sarepta Therapeutics Stock Headed to Over $200 a Share?” released on June 21, 2018, “Gene Therapy For Duchenne” on June 20, 2018, “Why Sangamo Therapeutics Stock Is Spiking Today” with a publish date: June 20, 2018, “3 Biotech Stocks That Soared This Week: Are They Buys?” and the last “Sarepta Therapeutics: Chasing The Good News” with publication date: June 21, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: